Document:

<PAGE>   1

                                                                EXHIBIT 10.45(A)

March 21, 2001

Mr. Abraham Cohen
Chugai Pharmaceuticals
444 Madison Avenue
12th Floor
New York, NY 10022

Dear Mr. Cohen:

This letter is to confirm our mutual understanding with respect to the terms and
conditions under which you agree to provide Viragen Inc. ("Viragen"), directly
or through its subsidiaries, affiliated and associated companies, with services
in a consulting capacity during the period beginning April 1, 2001 and ending
March 31, 2003 (hereinafter referred to as the "CONSULTING PERIOD"), it being
understood that this CONSULTING PERIOD may be extended by mutual agreement in
writing.

1.       "Consulting capacity" herein means that you will provide VIRAGEN with
         the full benefit of your knowledge, experience and skill with respect
         to questions and problems which VIRAGEN will stipulate. During the term
         of this Agreement, Abraham Cohen shall generally render advice and
         counsel on pharmaceutical and biotech related projects.

2.       VIRAGEN acknowledges that other clients may use your consulting
         services and it is understood and agreed that you are not to disclose
         to VIRAGEN any confidential information of other parties, including
         past and present clients. VIRAGEN will rely upon your ethical judgment
         to avoid conflicts of interest. It is understood and agreed that during
         the CONSULTING PERIOD you shall not consult for other parties regarding
         the same subject matter set forth above for the consulting capacity
         covered by this Agreement.

3.       You will make yourself available to VIRAGEN from time-to-time for
         consulting services in the consulting capacity stated herein.

4.       VIRAGEN agrees to compensate you as follows:

         a)       First Year Options:
                  Options on 100,000 shares of Viragen Common Stock at market
                  price at the date of grant (coincides with date of execution
                  of agreement). One-half vests upon execution of consultant
                  agreement and one-half vests 6 months from date of execution
                  of the consultant agreement.

         b)       Second Year Options:
                  Option on 100,000 shares of Viragen Common Stock at market
                  price at the date of grant (coincides with date of execution
                  of agreement). One-half vests upon the first anniversary of
                  the date of execution of the consultant agreement and one-half
                  vests 18 months from the date of execution of the consultant
                  agreement.

         In the event that you provide consulting service at a location away
         from the metropolitan area of your regular place of business, VIRAGEN
         will reimburse you for reasonable travel and living expenses incurred
         by you, provided that travel time shall not be considered time spent in
         the

<PAGE>   2

Abraham Cohen
Consulting Agreement
March 16, 2001
Page 2 of 3 Pages

         service of VIRAGEN in a consulting capacity. It is understood and
         agreed that VIRAGEN will stipulate in advance in writing the places and
         locations where you will provide services in a consulting capacity.
         Payment for your expenses will be made upon submission by you and
         approval by VIRAGEN of an itemized account of the expenses incurred and
         payments due. All payments shall be made by check payable to Abraham
         Cohen at Chugai Pharmaceuticals, 444 Madison Avenue, 12th Floor, New
         York, NY 10022. No payments will be made until you provide a taxpayer
         identification number.

5.       During the discussions leading up to this Agreement and during the
         CONSULTING PERIOD and any extensions thereof you have acquired and will
         acquire from VIRAGEN information which VIRAGEN considers to be
         proprietary and confidential, for example, information with respect to
         materials, compounds, formulations, samples, processes, methods,
         apparatus, operations and present and future plans of VIRAGEN. You
         agree to keep confidential and not to use, except in connection with
         services in a consulting capacity provided VIRAGEN, all such
         information, as well as all information developed by you as a result of
         your services to VIRAGEN under this Agreement, and not to divulge any
         such information to others at any time. Upon termination of this
         Agreement or at any other time VIRAGEN requests, you will transmit to
         VIRAGEN any written, printed or other materials embodying such
         information, including all copies, excerpts thereof, and samples given
         to you or prepared by you in connection with your work for VIRAGEN
         under this Agreement. These obligations on your part with respect to
         VIRAGEN information shall continue at all times beyond the CONSULTING
         PERIOD and any extensions thereof.

         Notwithstanding the above, this Agreement shall not restrict your use
         or disclosure of information which:

         a)       is or later becomes publicly known through no fault of yours;

         b)       was already known to you as evidenced by your written records
                  at the time of its receipt from VIRAGEN; or

         c)       is lawfully and in good faith made available to you without
                  restriction on disclosure or use by a third party.

         Specific information disclosed to you by VIRAGEN shall not be deemed to
         be available to the public or in your prior possession merely because
         it is embraced by more general information available to the public or
         in your prior possession.

6.       Any and all information, inventions and discoveries, whether or not
         patentable, which you develop, conceive and/or make:

         a)       within the CONSULTING PERIOD and any extensions mutually
                  agreed upon and which are related to any questions or problems
                  with respect to which VIRAGEN has utilized your services under
                  this Agreement, and/or

         b)       as a result of confidential information received from VIRAGEN,
                  shall be the sole and exclusive property of VIRAGEN. You will,
                  upon request of VIRAGEN, promptly execute any and all
                  applications, assignments or other instruments which VIRAGEN
                  shall deem necessary or

<PAGE>   3

Abraham Cohen
Consulting Agreement
March 16, 2001
Page 3 of 3 Pages

                  useful in order to apply for and obtain patent protection
                  worldwide for said inventions and discoveries, and in order to
                  assign and convey to VIRAGEN the sole and exclusive right,
                  title and interest in and to said inventions and discoveries
                  and patent applications and patents thereon. VIRAGEN will bear
                  the costs of preparation and filing of all said patent
                  applications.

7.       While providing services for VIRAGEN in a consulting capacity you will
         be acting as an independent contractor and not as an employee or agent
         of VIRAGEN and you will not be entitled to any of the benefits, direct
         or indirect, of an employee of VIRAGEN.

8.       The validity, interpretation and performance of this Agreement and any
         dispute connected herewith shall be governed and construed in
         accordance with the laws of the State of Florida, USA.

9.       The parties agree that all works created pursuant to this Agreement are
         deemed to be assigned to VIRAGEN, including all copyrights throughout
         the world. You agree to execute any documents deemed necessary by
         VIRAGEN to record said assignments. You shall also secure for VIRAGEN
         the assignment of copyrights in any work created by others pursuant to
         this Agreement, and shall notify VIRAGEN prior to commencing any
         activity toward creation if the copyright of any such work cannot be
         secured. The parties agree that all works made for hire under this
         Agreement shall vest in VIRAGEN.

10.      VIRAGEN will not be liable for any loss, injury or damage incurred by
         you or by a third party as a result of your performance of the
         services, including any loss, injury or damage resulting from the
         negligent or willful act or omission by you. You shall indemnify and
         hold VIRAGEN harmless from any liability, loss, cost, and expense
         (including attorneys' fees and costs) incurred by VIRAGEN as a result
         of your breach of this agreement, negligence or willful misconduct.
         This obligation shall survive the expiration or earlier termination of
         this agreement.

If the foregoing terms and conditions meet with your understanding and approval,
please show your acceptance and agreement by signing this letter in duplicate at
the place indicated below.

Very truly yours,

VIRAGEN, INC.

By: /s/ Gerald Smith                       By: /s/ Abraham Cohen
    --------------------------------           ---------------------------------
    Gerald Smith                               Abraham Cohen
    Chairman & CEO                             Title:
                                                    ----------------------------
                                              SS#:
                                                    ----------------------------
                                              Telephone No.
                                                           ---------------------

<PAGE>   4

                                                                EXHIBIT 10.45(B)

                             STOCK OPTION AGREEMENT

STOCK OPTION AGREEMENT, dated as of the Effective Date of Optionee's Consulting
Agreement (the "Effective Date" or "Grant Date") between Viragen, Inc. a
Delaware Corporation (the "Company") and Abraham Cohen ("Optionee").

The Company, pursuant to the provisions of its 1997 Stock Option Plan (the
"Plan"), hereby grants to Optionee an Option to acquire 200,000 shares of Common
Stock, par value $.01 per share, of the Company (the "Common Stock"), subject to
the following terms and conditions:

         1.       Grant of Option. The Company hereby grants to Optionee (the
"Option") to purchase up to 200,000 shares of Common Stock (the "Shares"), to be
transferred upon the exercise thereof, fully paid and nonassessable.

         2.       Exercise Price. The exercise price of the Shares subject to
the Option shall be the closing market price on the Effective Date, $1.20 per
share. The Company shall pay all original issue or transfer taxes upon the
exercise of the Option by Optionee.

         3.       Exercisability of Option; Rights and Privileges. Subject to
the provisions of Paragraph 6 hereof, the Option shall be exercisable by
Optionee: (i) 50,000 upon the Effective Date; (ii) 50,000 upon six (6) months
following the Effective Date; (iii) 50,000 upon the first anniversary of the
Effective Date and (iv) 50,000 upon eighteen (18) months following the Effective
Date (the "Exercise Date(s)") for a period of five (5) years from each Exercise
Date (the "Exercise Period").

                  All granted but unexercised Options shall continue to be fully
exercisable in accordance with the provisions herein:

                           (i)      if there occurs any corporate transaction
(which shall include a series of corporate transactions occurring within 60 days
or occurring pursuant to a plan), that has the result that shareholders of the
Company immediately before such transaction cease to own at least 66 2/3 percent
of the voting stock of the Company in a (a) reorganization, (b) consolidation,
(c) merger, (d) liquidation or (e) a similar corporate transaction;

                           (ii)     if the shareholders of the Company shall
approve a plan of merger, consolidation, reorganization, liquidation or
dissolution in which the Company does not survive (unless the approved merger,
consolidation, reorganization, liquidation or dissolution is subsequently
abandoned); or

<PAGE>   5

                           (iii)    if the shareholders of the Company shall
approve a plan for the sale, lease, exchange or other disposition of all or
substantially all the property and assets of the Company (unless such plan is
subsequently abandoned).

         4.       Non-Assignability of Option. The Option shall not be given,
granted, sold, exchanged, transferred, pledged, encumbered, assigned or
otherwise disposed of by Optionee, other than by will, the laws of descent and
distribution, estate planning purposes or assignment to a personal or family
related trust, and during the lifetime of Optionee, shall not be exercisable by
any other person, but only by Optionee.

         5.       Method of Exercise of Option. Optionee shall notify the
Company by written notice, in the form of the Notice of Exercise attached hereto
(Attachment A), delivered to the Company's principal office, attention: Chief
Financial Officer. Payment for the Shares shall be made by Optionee's check
payable to the order to the Company in full payment for the total exercise price
of the number of Shares purchased accompanying the Notice of Exercise. As soon
as practicable after the receipt of such Notice of Exercise and accompanying
payment for the purchase of Shares, the Company shall, at its principal office,
tender to Optionee a certificate or certificates issued in Optionee's name
evidencing the Shares purchased by Optionee hereunder.

         6.       Termination of Option. To the extent exercisable but not
exercised, the Option shall terminate upon the first to occur of the following
dates:

                  (a)      five (5) years from each Exercise Date as defined
herein if still serving as a director of the Company; or

                  (b)      the expiration of ninety (90) days following the date
Optionee ceases to serve a director of the Company and/or any of its
subsidiaries in the event of normal retirement or voluntary termination.

                  Subject to the provisions of this paragraph, in the event of
Optionee's death, the exercisable but unexercised portion of the Option may be
exercised by the estate of Optionee, or by the person who acquired the right to
exercise the Option by bequest or inheritance or by reason of the death of
Optionee.

         7.       Securities Laws. Employer represents and warrants that (i) all
shares underlying the Options will be issued from shares authorized by and
subject to the provisions of the Plan; (ii) the Plan and the shares underlying
the Options have been registered under the applicable regulations of the
Securities and Exchange Commission on Form S-8; and (iii) such registration
covering the shares underlying the Options will be maintained as effective for
the duration of the Exercise Period of the Options as defined herein.

                                       2
<PAGE>   6

         8.       Adjustment of Shares. If at any time prior to the expiration
or exercise in full of the Option, there shall be any increase or decrease in
the number of issued and outstanding shares of the Common Stock through the
declaration of a stock dividend or through any recapitalization resulting in a
stock split-up, combination or exchange of the Common Stock, then and in such
event:

                  (i)      appropriate adjustment shall be made in the maximum
number of Shares available for grant, so that the same percentage of the
Company's issued and outstanding Shares shall continue to be subject to being so
optioned; and

                  (ii)     appropriate adjustment shall be made in the number of
Shares, and the exercise price per Share thereof, that remain unexercised under
the Option, so that the same percentage of the Company's issued and outstanding
shares of Common Stock shall remain subject to purchase at the same aggregate
exercise price.

                  Except as otherwise expressly provided herein, the issuance by
the Company of shares of its capital stock of any class, or securities
convertible into shares of capital stock of any class, either in connection with
a direct sale of upon the exercise of rights or warrants to subscribe therefore,
or upon conversions of shares or obligations the Company convertible into such
shares or other securities, shall not affect, and no adjustment by reason
thereof shall be made with respect to, the number or exercise price of the
Shares that remain unexercised under the Option.

                  Without limiting the generality of the foregoing, the
existence of unexercised Shares under the Option shall not affect in any manner
the right or power of the Company to make, authorize or consummate (i) any or
all adjustments, recapitalizations, reorganizations or other changes in the
Company's capital structure or its business; (ii) any merger or consolidation of
the Company; (iii) any issue by the Company of debt securities, or preferred or
preference stock that would rank above the Shares issuable upon exercise of the
Option; (iv) the dissolution or liquidation of the Company; (v) any sale,
transfer or assignment of all or any part of the assets or business of the
Company; or (vi) any other corporate act or proceeding, whether of a similar
character or otherwise.

         9.       No Rights as Stockholder. Optionee shall have no rights as a
stockholder of the Company in respect of the Shares as to which the Option shall
not have been exercised and payments made therefore as herein provided.

         10.      Binding Effect. Except as otherwise provided herein, this
Agreement shall be binding upon and inure to the benefit of the parties hereto,
their heirs, legal representatives, successors and permitted assigns. Optionee
acknowledges that Optionee has read and understands the Plan and agrees to abide
by its terms.

         11.      Governing Law. This Agreement shall be governed by and
construed in accordance with the laws of the State of Delaware, without giving
effect to the conflict of

                                       3
<PAGE>   7

laws principles thereof. All terms not defined in this Agreement shall have the
same meaning as in the Plan.

         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
day and year first above written.

                                                 VIRAGEN, INC.

                                           By: /s/ Dennis W. Healey
                                               --------------------------------
                                               Dennis W. Healey
                                               Executive Vice President & CFO

                                                 OPTIONEE

                                                /s/ Abraham Cohen
                                                --------------------------------
                                                Abraham Cohen

                                       4
<PAGE>   8

                                  ATTACHMENT A

                               NOTICE OF EXERCISE

The undersigned hereby irrevocably elects to exercise the within Option to the
extent of purchasing __________ shares of Common Stock of Viragen, Inc., a
Delaware Corporation, and hereby makes payments of $________ in payment
therefor.

                                            --------------------------
                                            Signature

                                            --------------------------
                                            Date

            INSTRUCTIONS FOR ISSUANCE OF STOCK AND CORPORATE RECORDS

Name:
                  ---------------------------------------------
                  (Please type or print in block letters)

Address:
                  ---------------------------------------------

                  ---------------------------------------------

Social  Security #:
                  ---------------------------------------------

Phone #: (    )
          ---- ------------------------------------------------

Fax #:   (    )
          ---- ------------------------------------------------

                                       5<PAGE>   1

                                                                   EXHIBIT 10.47

May 23, 2001

Mr. Robert C. Salisbury
3252 Walter Travis Drive
Sarasota, FL 34240

Dear Mr. Salisbury:

This letter is to confirm our mutual understanding with respect to the terms and
conditions under which you agree to provide Viragen Inc. ("Viragen"), directly
or through its subsidiaries, affiliated and associated companies, with services
in a consulting capacity during the period beginning June 1, 2001 and ending May
31, 2004 (hereinafter referred to as the "CONSULTING PERIOD"), it being
understood that this CONSULTING PERIOD may be extended by mutual agreement in
writing.

5.       "Consulting capacity" herein means that you will provide VIRAGEN with
         the full benefit of your knowledge, experience and skill with respect
         to strategic planning, questions, collaborations or partnering
         arrangements in pharmaceutical and/or biotech related projects. It is
         anticipated that you will initially focus your efforts on VIRAGEN's
         oncology related projects.

6.       VIRAGEN acknowledges that other clients may use your consulting
         services and it is understood and agreed that you are not to disclose
         to VIRAGEN any confidential information of other parties, including
         past and present clients. VIRAGEN will rely upon your ethical judgment
         to avoid conflicts of interest. It is understood and agreed that during
         the CONSULTING PERIOD you shall not consult for other parties regarding
         the same subject matter set forth above for the consulting capacity
         covered by this Agreement.

7.       You will make yourself available to VIRAGEN from time-to-time for
         consulting services in the consulting capacity stated herein.

8.       VIRAGEN agrees to compensate you as follows:

         a)       Reimbursement of actual expenses incurred.

         b)       Warrant grants to purchase VIRAGEN, Inc. common stock upon
                  meeting of the following milestones identified and sourced
                  through your efforts:

                  i)       10,000 shares upon the delivery of an agreed plan of
                           action from the development and collaboration of the
                           three oncology projects.

                  ii)      50,000 shares upon the signing of a definitive
                           licensing/collaboration agreement with a
                           pharmaceutical or biotech partner.

                  iii)     25,000 shares upon the Viragen's receipt of the first
                           $1 million in aggregate milestone, licensing fees
                           and/or equity investments from the pharmaceutical or
                           biotech partner.

                  iv)      25,000 shares upon the Viragen's receipt of the
                           second $1 million in aggregate milestone, licensing
                           fees and/or equity investments from the
                           pharmaceutical or biotech partner.

<PAGE>   2

Robert C. Salisbury
Consulting Agreement
May 23, 2001
Page 2 of 3 Pages

         c)       The warrants shall have an exercise price equal to 115% of the
                  fair market value of the Viragen stock upon the date of the
                  grant and would expire five years from the date of the grant.
                  The warrants will be exercisable 50% one year after the date
                  of grant, 50% two years after the date of the grant.

5.       During the discussions leading up to this Agreement and during the
         CONSULTING PERIOD and any extensions thereof you have acquired and will
         acquire from VIRAGEN information which VIRAGEN considers to be
         proprietary and confidential, for example, information with respect to
         materials, compounds, formulations, samples, processes, methods,
         apparatus, operations and present and future plans of VIRAGEN. You
         agree to keep confidential and not to use, except in connection with
         services in a consulting capacity provided VIRAGEN, all such
         information, as well as all information developed by you as a result of
         your services to VIRAGEN under this Agreement, and not to divulge any
         such information to others at any time. Upon termination of this
         Agreement or at any other time VIRAGEN requests, you will transmit to
         VIRAGEN any written, printed or other materials embodying such
         information, including all copies, excerpts thereof, and samples given
         to you or prepared by you in connection with your work for VIRAGEN
         under this Agreement. These obligations on your part with respect to
         VIRAGEN information shall continue at all times beyond the CONSULTING
         PERIOD and any extensions thereof.

         Notwithstanding the above, this Agreement shall not restrict your use
         or disclosure of information which:

         a)       is or later becomes publicly known through no fault of yours;

         b)       was already known to you other than as a result of any
                  existing fiduciary capacity with VIRAGEN as evidenced by your
                  written records at the time of its receipt from VIRAGEN; or

         c)       is lawfully and in good faith made available to you without
                  restriction on disclosure or use by a third party.

         Specific information disclosed to you by VIRAGEN shall not be deemed to
         be available to the public or in your prior possession merely because
         it is embraced by more general information available to the public or
         in your prior possession.

6.       Any and all information, inventions and discoveries, whether or not
         patentable, which you develop, conceive and/or make:

         a)       within the CONSULTING PERIOD and any extensions mutually
                  agreed upon and which are related to any questions or problems
                  with respect to which VIRAGEN has utilized your services under
                  this Agreement, and/or

         b)       as a result of confidential information received from VIRAGEN,
                  shall be the sole and exclusive property of VIRAGEN. You will,
                  upon request of VIRAGEN, promptly execute any and all
                  applications, assignments or other instruments which VIRAGEN
                  shall deem necessary or useful in order to apply for and
                  obtain patent protection worldwide for said inventions and
                  discoveries, and in order to assign and convey to VIRAGEN the
                  sole and exclusive right, title and interest in and to said
                  inventions and discoveries and patent applications and patents
                  thereon. VIRAGEN will bear the costs of preparation and filing
                  of all said patent applications.

<PAGE>   3

Robert C. Salisbury
Consulting Agreement
May 23, 2001
Page 3 of 3 Pages

7.       While providing services for VIRAGEN in a consulting capacity you will
         be acting as an independent contractor and not as an employee or agent
         of VIRAGEN and you will not be entitled to any of the benefits, direct
         or indirect, of an employee of VIRAGEN.

8.       The validity, interpretation and performance of this Agreement and any
         dispute connected herewith shall be governed and construed in
         accordance with the laws of the State of Florida, USA.

9.       The parties agree that all works created pursuant to this Agreement are
         deemed to be assigned to VIRAGEN, including all copyrights throughout
         the world. You agree to execute any documents deemed necessary by
         VIRAGEN to record said assignments. You shall also secure for VIRAGEN
         the assignment of copyrights in any work created by others pursuant to
         this Agreement, and shall notify VIRAGEN prior to commencing any
         activity toward creation if the copyright of any such work cannot be
         secured. The parties agree that all works made for hire under this
         Agreement shall vest in VIRAGEN.

10.      VIRAGEN will not be liable for any loss, injury or damage incurred by
         you or by a third party as a result of your performance of the
         services, including any loss, injury or damage resulting from the
         negligent or willful act or omission by you. You shall indemnify and
         hold VIRAGEN harmless from any liability, loss, cost, and expense
         (including attorneys' fees and costs) incurred by VIRAGEN as a result
         of your breach of this agreement, negligence or willful misconduct.
         This obligation shall survive the expiration or earlier termination of
         this agreement.

If the foregoing terms and conditions meet with your understanding and approval,
please show your acceptance and agreement by signing this letter in duplicate at
the place indicated below.

Very truly yours,

VIRAGEN, INC.

By: /s/ Gerald Smith                     By: /s/ Robert C. Salisbury
    -----------------------------            --------------------------------
    Gerald Smith                             Robert C. Salisbury
    Chairman & CEO                           Title:
                                                   --------------------------
                                             SS#:
                                                  ---------------------------
                                             Telephone No.
                                                          -------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]